Clinical trials: Coronary Patient
Heart Failure, Mitral Regurgitation
Study of Safety and Efficacy of the Percutaneous Reduction of Mitral Valve Regurgitation in Heart Failure Patients
Improvement in heart failure with moderate to severe mitral regurgitation using a percutaneously delivered implantable device.
- Trial name
- PTOLEMY-2 (NCT00787293)
- Testing
- PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
- Where
- 13 sites in Belgium, Czechia and 3 more
- Volunteers
- 30 people
- Sponsor
- Viacor
Heart Failure
A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure
This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure.
- Trial name
- NCT01125514
- Testing
- Aliskiren 150 mg, Furosemide 60 mg, Aliskiren 300 mg
- Where
- 2 sites in Germany, Lithuania
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Atrioventricular Block, Heart Diseases
Biventricular Versus Right Ventricular Pacing in Heart Failure Patients With Atrioventricular Block (BLOCK HF)
Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.
- Trial name
- BLOCK HF (NCT00267098)
- Testing
- Cardiac Resynchronization Therapy (CRT)
- Where
- 54 sites in United States, Canada
- Volunteers
- 918 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Coronary Artery Disease (CAD), Renal Impairment
Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography
The study is to evaluate and compare the effects on kidney function of three iodinated contrast media (CM) in patients at risk of kidney damage evaluating serum creatinine (Scr) concentrations up to three days after CM…
- Conditions
- Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
- Trial name
- NCT00335101
- Testing
- Iodixanol, Ioversol, Iopromide
- Where
- 2 sites in United States, Germany
- Sponsor
- GE Healthcare
Paroxysmal Atrial Fibrillation
A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
- Trial name
- NCT00540787
- Testing
- Radiofrequency ablation, antiarrhythmic drugs, Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs, ThermoCool Radiofrequency Catheter
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 112 people
- Sponsor
- Biosense Webster, Inc.
CHF, Congestive Heart Failure
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF
Sensorum Health (Sensorum) is conducting a pilot study to determine if Sensorum's proprietary passive sensor network can be used to identify signals of early health decompensation in subjects prior to a hospitalization for…
- Trial name
- NCT05865197
- Testing
- Data collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sensorum Health Inc.
Coronary Heart Disease
Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
This study is designed to verify the safety and efficacy of Lepu® NeoVas™ Bioabsorbable Coronary Artery Rapamycin-eluting Stent System combined with different antiplatelet therapies in the treatment of coronary heart disease.
- Trial name
- NCT04995159
- Testing
- Single anti-platelet therapy, Dual anti-platelet therapy
- Where
- 114 sites in China
- Volunteers
- 2,150 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Atrial Fibrillation
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
Primary Objective: To determine whether daily administration of dronedarone started 5-7 days before cardioversion is superior to dronedarone started only after cardioversion with respect to the absence of symptomatic, ECG…
- Trial name
- NCT01026090
- Testing
- Dronedarone
- Where
- 43 sites in Canada
- Volunteers
- 292 people
- Sponsor
- Sanofi
Chronic Heart Failure With Reduced Ejection Fraction
A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of…
- Trial name
- ASTRAAS-HF (NCT04836182)
- Testing
- IONIS-AGT-LRx
- Where
- 19 sites in United States, Hungary and 1 more
- Volunteers
- 72 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Reduced Ejection Fraction
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients
Cognitive impairment (CI) is highly prevalent in patients with heart failure with reduced ejection fraction (HFrEF), which has significant implications for disease management, quality of life and clinical outcomes.
- Trial name
- LYRIC-HF (NCT07695090)
- Testing
- Lumacaftor 200 MG
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Qanatpharma AG
Coronary Artery Disease, Coronary Stenosis
TARGET-PREMIER Trail in Evaluating the Safety and Efficacy of the Rapamycin Target Eluting Stent in CAS Treatment
The aim of the TARGET PREMIER trail in to demonstrate the safety and efficacy of the rapamycin target eluting stent in the treatment of subjects with ischemic heart disease (asymptomatic myocardial ischemia , table or unstable…
- Trial name
- T-P (NCT04951050)
- Testing
- Rapamycin target eluting stent
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Aortic Valve Stenosis
Medtronic CoreValve REDO Study
The proposed investigation is a prospective, multicenter, non-randomized study to evaluate the immediate benefits (at discharge and at 30 days) in terms of performance and safety of the implantation of the Medtronic CoreValve PAV…
- Trial name
- REDO (NCT01051310)
- Testing
- Medtronic CoreValve System
- Where
- 3 sites in Germany, Netherlands
- Volunteers
- 18 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
Correlating Noninvasive Cardiovascular Measures to Left Ventricular End Diastolic Pressure in Heart Failure
HF001 is a prospective observational study utilizing non-invasive medical devices that may be able to discriminate changes in heart failure while acutely decompensated patients undergo routine interventional therapies in a…
- Trial name
- NCT02406820
- Testing
- Non-invasive hemodynamic monitoring (CVInsight™ [CVI])
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Intelomed, Inc.
Atrial Fibrillation, Obesity
Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare
The overall objective of this analysis is to understand patient characteristics, the use of treatment, and clinical outcomes among obese (overweight) and severely obese patients with non-valvular atrial fibrillation (NVAF) who…
- Conditions
- Atrial Fibrillation, Obesity, Anticoagulants
- Trial name
- NCT04681482
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 107,383 people
- Sponsor
- Pfizer
Congestive Heart Failure
Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients
Track changes in non-invasive central venous pressure across hospital stay and relationship with readmission
- Trial name
- NCT05441696
- Testing
- ezCVP measurement
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Nihon Kohden
Hypertension
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
This is a Phase 4, prospective, multi-centric and randomized controlled study to compare the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous system's (SNS) activity in subjects with…
- Trial name
- NCT01251146
- Testing
- Bisoprolol, Atenolol
- Where
- 2 sites in China
- Volunteers
- 177 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Sudden Cardiac Death, Ventricular Fibrillation
LifeVest Post-CABG Registry
This is a multi-center prospective registry of patients with an ejection fraction (EF) ≤ 35% following coronary artery bypass graft (CABG) surgery in order to test the hypothesis that wearable defibrillators (WD) will decrease…
- Conditions
- Sudden Cardiac Death, Ventricular Fibrillation, Ventricular Tachycardia, Ventricular Dysfunction
- Trial name
- NCT01448005
- Testing
- wearable defibrillator (LifeVest)
- Where
- 5 sites in United States
- Volunteers
- 69 people
- Sponsor
- Zoll Medical Corporation
Mitral Regurgitation, Mitral Valve Regurgitation
Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) and COAPT CAS
The purpose of the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial is to confirm the safety and effectiveness of the MitraClip…
- Conditions
- Mitral Regurgitation, Mitral Valve Regurgitation, Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects, Heart Failure
- Trial name
- COAPT (NCT01626079)
- Testing
- MitraClip System
- Where
- 86 sites in United States, Canada
- Volunteers
- 776 people
- Sponsor
- Abbott Medical Devices
Ventricular Arrythmias
Efficacy of the ATP Switch Automatic Programming in Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) Implanted Patients
Primary objective is to assess the efficacy of the new ATP Autoswitch function in simple, dual or triple chamber ICD.
- Trial name
- ASAP (NCT01169246)
- Where
- France
- Volunteers
- 1,254 people
- Sponsor
- MicroPort CRM
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.